Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Desai is currently serving the company as Group Finance Controller
Winlevi is authorized in EU for the treatment of acne vulgaris
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
The partnership combines Croda’s deep expertise in smart science and global market reach with Amino’s advanced capabilities in precision manufacturing of amino acids
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Subscribe To Our Newsletter & Stay Updated